These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 28549390)

  • 1. Clinical and molecular monitoring of Plasmodium falciparum resistance to antimalarial drug (artesunate+sulphadoxine-pyrimethamine) in two highly malarious district of Madhya Pradesh, Central India from 2012-2014.
    Mishra S; Bharti PK; Shukla MM; Ali NA; Kashyotia SS; Kumar A; Dhariwal AC; Singh N
    Pathog Glob Health; 2017 Jun; 111(4):186-194. PubMed ID: 28549390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.
    Atroosh WM; Al-Mekhlafi HM; Snounou G; Al-Jasari A; Sady H; Nasr NA; Lau YL; Surin J
    Malar J; 2016 May; 15(1):295. PubMed ID: 27234587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequencies distribution of dihydrofolate reductase and dihydropteroate synthetase mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum population from Hadhramout Governorate, Yemen.
    Bamaga OA; Mahdy MA; Lim YA
    Malar J; 2015 Dec; 14():516. PubMed ID: 26693691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable high frequencies of sulfadoxine-pyrimethamine resistance associated mutations and absence of K13 mutations in Plasmodium falciparum 3 and 4 years after the introduction of artesunate plus sulfadoxine-pyrimethamine in Ujjain, Madhya Pradesh, India.
    Pathak A; Mårtensson A; Gawariker S; Sharma A; Diwan V; Purohit M; Ursing J
    Malar J; 2020 Aug; 19(1):290. PubMed ID: 32795288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prevalence of pfdhfr and pfdhps mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Jazan Region, Southwestern Saudi Arabia: important implications for malaria treatment policy.
    Madkhali AM; Al-Mekhlafi HM; Atroosh WM; Ghzwani AH; Zain KA; Abdulhaq AA; Ghailan KY; Anwar AA; Eisa ZM
    Malar J; 2020 Dec; 19(1):446. PubMed ID: 33267841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of pfdhfr-pfdhps triple mutations associated with anti-malarial drugs resistance in Plasmodium falciparum isolates seven years after the adoption of sulfadoxine-pyrimethamine in combination with artesunate as first-line treatment in Iran.
    Rouhani M; Zakeri S; Pirahmadi S; Raeisi A; Djadid ND
    Infect Genet Evol; 2015 Apr; 31():183-9. PubMed ID: 25653131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies.
    Adeel AA; Elnour FA; Elmardi KA; Abd-Elmajid MB; Elhelo MM; Ali MS; Adam MA; Atta H; Zamani G; Warsame M; Barrette A; Mohammady HE; Nada RA
    Malar J; 2016 May; 15(1):285. PubMed ID: 27209063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical and molecular study of artesunate + sulphadoxine-pyrimethamine in three districts of central and eastern India.
    Srivastava P; Ratha J; Shah NK; Mishra N; Anvikar AR; Sharma SK; Das MK; Srivastava B; Valecha N
    Malar J; 2013 Jul; 12():247. PubMed ID: 23866298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the efficacy of antimalarial medicines in India via sentinel sites: Outcomes and risk factors for treatment failure.
    Mishra N; Srivastava B; Bharti RS; Rana R; Kaitholia K; Anvikar AR; Das MK; Ghosh SK; Bhatt RM; Tyagi PK; Dev V; Phookan S; Wattal SL; Sonal GS; Dhariwal AC; Valecha N
    J Vector Borne Dis; 2016; 53(2):168-78. PubMed ID: 27353588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of molecular markers of sulfadoxine-pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan.
    Yaqoob A; Khattak AA; Nadeem MF; Fatima H; Mbambo G; Ouattara A; Adams M; Zeeshan N; Takala-Harrison S
    Malar J; 2018 Dec; 17(1):471. PubMed ID: 30558587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction.
    Awab GR; Imwong M; Pukrittayakamee S; Alim F; Hanpithakpong W; Tarning J; Dondorp AM; Day NP; White NJ; Woodrow CJ
    Malar J; 2016 Feb; 15():121. PubMed ID: 26917051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Evidence for
    Wedam J; Tacoli C; Gai PP; Siegert K; Kulkarni SS; Rasalkar R; Boloor A; Jain A; Mahabala C; Baliga S; Shenoy D; Devi R; Gai P; Mockenhaupt FP
    Am J Trop Med Hyg; 2018 Dec; 99(6):1508-1510. PubMed ID: 30398146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.
    Mohapatra PK; Sarma DK; Prakash A; Bora K; Ahmed MA; Sarma B; Goswami BK; Bhattacharyya DR; Mahanta J
    PLoS One; 2014; 9(9):e105562. PubMed ID: 25184337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant.
    Fernandes N; Figueiredo P; do Rosário VE; Cravo P
    Malar J; 2007 Mar; 6():35. PubMed ID: 17378942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular surveillance of anti-malarial drug resistance genes in Plasmodium falciparum isolates in Odisha, India.
    Rana R; Khan N; Sandeepta S; Pati S; Das A; Bal M; Ranjit M
    Malar J; 2022 Dec; 21(1):394. PubMed ID: 36566182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacies of artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and pfdhps genes in tea gardens of Jalpaiguri District, India.
    Saha P; Guha SK; Das S; Mullick S; Ganguly S; Biswas A; Bera DK; Chattopadhyay G; Das M; Kundu PK; Ray K; Maji AK
    Antimicrob Agents Chemother; 2012 May; 56(5):2511-7. PubMed ID: 22314538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in pfdhfr and pfdhps genes after five years of artemisinin combination therapy (ACT) implementation from urban Kolkata, India.
    Chatterjee M; Ganguly S; Saha P; Guha SK; Maji AK
    Infect Genet Evol; 2017 Sep; 53():155-159. PubMed ID: 28533179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré.
    Bonnet M; Roper C; Félix M; Coulibaly L; Kankolongo GM; Guthmann JP
    Malar J; 2007 May; 6():54. PubMed ID: 17477865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria from three highly malarious states in India.
    Bharti PK; Shukla MM; Ringwald P; Krishna S; Singh PP; Yadav A; Mishra S; Gahlot U; Malaiya JP; Kumar A; Prasad S; Baghel P; Singh M; Vadadi J; Singh MP; Bustos MD; Ortega LI; Christophel EM; Kashyotia SS; Sonal GS; Singh N
    Malar J; 2016 Oct; 15(1):498. PubMed ID: 27737665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disagreement in genotyping results of drug resistance alleles of the Plasmodium falciparum dihydrofolate reductase (Pfdhfr) gene by allele-specific PCR (ASPCR) assays and Sanger sequencing.
    Sharma D; Lather M; Dykes CL; Dang AS; Adak T; Singh OP
    Parasitol Res; 2016 Jan; 115(1):323-8. PubMed ID: 26407876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.